Background
==========

Peritoneal and omental calcification, including those of the psammomatous variety, are associated with a wide range of both benign and malignant abdominal pathologies. On occasion, psammomatous calcifications are associated with tumors such as metastatic ovarian cancer and phenotypically identical primary peritoneal serous papillary carcinoma or mesothelioma. Calcification can occur in primary tumors in peritoneal or omental tissues, as well as metastases \[[@b1-amjcaserep-21-e920487]\]. Conditions that systematically dysregulate calcium and mineral homeostasis, particularly hyperparathyroidism, can also cause development of calcified masses \[[@b2-amjcaserep-21-e920487]\].

A deposition of a mineral substance consisting of calcium phosphate molecules located outside of normal bone tissue is known as "heterotopic" or "dystrophic" calcification. Small calcified masses in the abdomen are generally asymptomatic and detectable through radiological methods such as contrast-enhanced CT scans. However, to identify their source, biopsy and histological analysis may be necessary \[[@b2-amjcaserep-21-e920487]\]. Larger masses that cause symptoms such as abdominal pain, discomfort, or bloating are more typically associated with malignant tumors than with benign processes \[[@b3-amjcaserep-21-e920487]\].

We present a unique case of chronic omental calcifications that persisted in a patient for more than 10 years before she became symptomatic. The onset of symptoms typical of malignant abdominal lesions, and the presence of a large, calcification-containing mass in the abdominal wall, raised the possibility that a benign or low-grade neoplasm had transformed into an overtly malignant tumor. Immunohistochemical staining of calcified sections revealed an expression profile consistent with well-differentiated papillary mesothelioma (WDPM) or papillary serous carcinoma (PSC), requiring more thorough analysis.

Case Report
===========

A 68-year-old woman presented with abdominal discomfort and recurrent diffuse abdominal pains associated with increasing omental calcifications. The patient had a 10-year history of omental calcifications, which had significantly increased in number and density in recent months. Her medical history included a hysterectomy due to a large, "grapefruit-like" mass (likely a leiomyoma), an appendectomy, and resection of a benign breast mass. The patient's mother had undergone a radical thyroidectomy due to "excessive growth", the precise nature of which was unknown to the patient. Additionally, the patient reported that her mother experienced episodic symptoms of diffuse abdominal pain and a feeling of fullness. This family history raised concerns about possible metastatic papillary thyroid carcinoma, which is known to be associated with psammomatous calcifications. The patient had no history of tobacco smoking, alcohol, or substance abuse.

An extensive workup was performed, including upper and lower gastrointestinal endoscopy to identify any obvious causes for her symptoms. A modification of the patient's diet and bowel regime failed to alleviate the symptoms, and there were no identified aggravating or relieving factors for the pain. In January 2019, after a worsening of symptoms and progressively increasing calcifications captured on imaging, the patient underwent elective abdominal surgery. During the operation, severe adhesions were observed in the right upper quadrant, likely as a result of her previous surgical procedures. A 4.0×3.5×1.0 cm mass comprised of mature adipose tissue was discovered in the abdominal wall. The mass was focally bounded by a thin fibrous layer, compatible with an encapsulated lipoma.

On further inspection, an 8.5×6.5×1.8 cm irregular intra-abdominal/mesenteric mass composed of yellow-red fatty tissue was discovered and excised. Microscopic sections contained fat with variable clustered classic/psammomatous calcifications. Some sections demonstrated a thin epithelioid periphery, in association with a very focal and subtle papillary surface epithelial/mesothelial proliferation ([Figure 1](#f1-amjcaserep-21-e920487){ref-type="fig"}).

Immunohistochemical staining showed that mesothelial cells in the mass presented as strongly positive for calretinin ([Figure 2](#f2-amjcaserep-21-e920487){ref-type="fig"}) and were focally positive for epithelial membrane antigen (EMA), CK903 (high-molecular keratin), and vimentin. Mesothelial cells also demonstrated strong nuclear positivity for the paired box 8 protein (PAX8) ([Figure 2](#f2-amjcaserep-21-e920487){ref-type="fig"}). Additional stains added in response to this pattern showed strong positivity for CK8, moderate positivity for BAP1, focal positivity for ER, minimal positivity for CD56, and negativity for CK5/6 and D2-40 ([Figure 2](#f2-amjcaserep-21-e920487){ref-type="fig"}).

The proliferative cells were strongly positive for some antibodies typically associated with mesothelial derivation but negative for others. Given this result and the fact that the cells were variably positive for antibodies conventionally associated with gynecologic malignancy, the case was seen by an expert consultant. The conferred differential diagnosis strongly favored papillary mesothelial hyperplasia/benign well-differentiated papillary mesothelioma, which is a benign, reactive phenomenon. The worrisome positive stains were noted to be positive at a low rate in most of this lesion. Despite the presence of calcifications lasting for at least 10 years, the new symptoms and laboratory findings raised the possibility of serous papillary carcinoma. Other diagnoses suggested by the immunohistochemistry and histological findings included reactive mesothelial hyperplasia (RMH) or WDPM. To help differentiate between these diagnoses, we conducted a literature search for WDPM case reports or case series. [Table 1](#t1-amjcaserep-21-e920487){ref-type="table"} is a summary of the observations from the literature search. [Table 2](#t2-amjcaserep-21-e920487){ref-type="table"} compares the immunohistochemical findings from this case versus WDPM, RMH, and PSC cases detailed in the literature.

The patient tolerated surgery well and recovered quickly, reporting complete relief of her symptoms at her 5-month follow-up appointment. She was worried about the inconclusive pathology; therefore, a referral was made for an expert opinion, which also favored benign pathology (WDPM).

Discussion
==========

Peritoneal and omental calcifications are broadly grouped into metastatic or heterotopic/dystrophic categories. Metastatic calcification is caused by systemic mineral imbalances throughout the body, whereas dystrophic calcification can arise from dead or damaged tissues as a result of injury, surgery, aging, or inflammation. It can also be associated with diseases, including infectious pathogens or malignancies (paraneoplastic) \[[@b1-amjcaserep-21-e920487],[@b2-amjcaserep-21-e920487]\]. In either case, calcium phosphate minerals are deposited in soft tissues of the body. Certain medical treatments, such as abdominal surgery, can also lead to the development of these calcified masses. Typically, small and asymptomatic calcifications are identified by CT scans of the region.

Large calcified masses that cause symptoms, such as abdominal discomfort, pain, bloating, appetite changes, or a feeling of fullness, are commonly indicative of a malignant etiology. Calcification of nodules within organs, rather than in the form of a thin lining of vessels or cavities, can also be a sign of malignancy \[[@b3-amjcaserep-21-e920487]\]. The most common diseases associated with malignant cases are ovarian cancer and tumors of the mesothelial or sub-mesothelial layers of the peritoneum. These include primary papillary serous peritoneal carcinoma or malignant mesothelioma \[[@b38-amjcaserep-21-e920487]\].

In women with normal-sized ovaries, carcinomatosis in the peritoneum may occur due to serous papillary carcinoma of the surface of the ovary \[[@b39-amjcaserep-21-e920487]\], or primary serous papillary carcinoma of the peritoneum. In addition, when differentiating between types of fat-containing tumors within the abdomen, the presence of calcified soft tissue can be a diagnostic clue. Synchronous fatty and calcified tissue can occur in teratomas, and, in rare cases, as calcification of lipomas \[[@b40-amjcaserep-21-e920487]\]. Calcification is also occasionally associated with WDPM, which is usually considered a tumor of no-to-low malignant potential. This differentiation is made more difficult by an identification that is often ancillary \[[@b38-amjcaserep-21-e920487],[@b41-amjcaserep-21-e920487]\].

WDPM is rare and distinct from malignant mesothelioma based on clinicopathology \[[@b19-amjcaserep-21-e920487],[@b20-amjcaserep-21-e920487],[@b38-amjcaserep-21-e920487],[@b42-amjcaserep-21-e920487]\]. WDPM most commonly occurs in women, spanning a wide age range, but usually occurs during the reproductive years. Primarily arising from the peritoneal surfaces of the abdomen and pelvis, WDPM can also occur in the pleura, pericardium, and tunica vaginalis \[[@b5-amjcaserep-21-e920487],[@b38-amjcaserep-21-e920487],[@b43-amjcaserep-21-e920487]\]. Clinically, it is often discovered incidentally during pelvic examination or surgery. Imaging features of WDPM are not well documented; however, peritoneal thickening, multiple peritoneal nodules (occasionally calcified), omental infiltration, and ascites have all been reported \[[@b44-amjcaserep-21-e920487],[@b45-amjcaserep-21-e920487]\]. In contrast to mesothelioma, WDPM is not commonly associated with asbestos exposure \[[@b5-amjcaserep-21-e920487],[@b38-amjcaserep-21-e920487]\]. The well-formed papillary architecture of WDPM superficially spreads and is lined by single layers of bland, cuboidal, or flattened mesothelial cells with little to no nuclear atypia, usually without mitoses \[[@b5-amjcaserep-21-e920487],[@b38-amjcaserep-21-e920487]\]. In some instances of WDPM, psammomatous bodies \[[@b8-amjcaserep-21-e920487],[@b11-amjcaserep-21-e920487],[@b15-amjcaserep-21-e920487],[@b16-amjcaserep-21-e920487],[@b20-amjcaserep-21-e920487],[@b21-amjcaserep-21-e920487]\] and invasive foci \[[@b5-amjcaserep-21-e920487],[@b6-amjcaserep-21-e920487]\] have been reported. In a recent study of 75 patients with WDPM \[[@b5-amjcaserep-21-e920487]\], the affected areas/nodules were generally less than 2 cm in diameter but ranged from 6 mm to 6.0 cm in diameter. Lesions greater than 2 cm were commonly hybrid tumors composed of WDPM combined with an adenomatoid tumor or multicystic mesothelioma \[[@b5-amjcaserep-21-e920487]\].

Where complete resection is possible, the prognosis is usually good. Typically, this includes an indolent post-surgical course and long/unaffected survival \[[@b38-amjcaserep-21-e920487],[@b44-amjcaserep-21-e920487]\]. However, based on the potential for recurrence or the risk of misdiagnosis of an under-sampled malignant mesothelioma, follow-up imaging is strongly recommended. There are rare case reports of WDPM progressing to true malignant peritoneal mesothelioma, which highlights the value of genetic (e.g., molecular) analysis of neoplasms in general, and WDPM/mesothelial proliferations in particular \[[@b11-amjcaserep-21-e920487],[@b12-amjcaserep-21-e920487],[@b41-amjcaserep-21-e920487],[@b45-amjcaserep-21-e920487]\].

We put forward three possible explanations for the phenomenon observed in the pathology slides: RMH showing peculiar psammomatous calcifications, multiple microscopic foci of benign WDPM, or the emergence of a low-grade serous papillary carcinoma of the peritoneum. Differentiating WDPM from other histologically similar disease processes in the peritoneum, such as serous papillary carcinoma and borderline RMH, can be difficult, but the identification can be aided by immunohistochemistry. In contrast to WDPM, RMH commonly has reactive alterations, inflammatory alterations, or both in adjacent serosa. It is also associated with a history of immune, cardiovascular, inflammatory, or toxic diseases \[[@b5-amjcaserep-21-e920487]\]. Sun et al. \[[@b5-amjcaserep-21-e920487]\] reported that desmin may be a useful marker to differentiate RMH from WDPM. Only 1 (2.6%) of their WDPM cases showed positive focal staining for desmin, which has been shown in different studies to be more commonly positive in RMH \[[@b5-amjcaserep-21-e920487],[@b26-amjcaserep-21-e920487],[@b46-amjcaserep-21-e920487]\].

In our case, focal EMA suggested a diagnosis of WDPM over RMH, as it is present in a higher percentage of cases of WDPM \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487],[@b7-amjcaserep-21-e920487],[@b9-amjcaserep-21-e920487],[@b18-amjcaserep-21-e920487]\] than RMH \[[@b5-amjcaserep-21-e920487],[@b22-amjcaserep-21-e920487],[@b25-amjcaserep-21-e920487],[@b26-amjcaserep-21-e920487]\]. Additionally, according to a study by Hoekman et al., EMA was focally present in all 3 of the cases of WDPM examined \[[@b19-amjcaserep-21-e920487]\]. In a 2017 study by Nautiyal et al. \[[@b22-amjcaserep-21-e920487]\], EMA was negative in all 11 RMH cases tested. Positive PAX8 staining is also more likely in WDPM \[[@b5-amjcaserep-21-e920487],[@b24-amjcaserep-21-e920487]\], but also occurs in many RMH cases, rendering it of little use as a diagnostic tool in this case. Likewise, the presence of vimentin \[[@b13-amjcaserep-21-e920487],[@b19-amjcaserep-21-e920487],[@b25-amjcaserep-21-e920487]\] and BAP-1 \[[@b10-amjcaserep-21-e920487],[@b29-amjcaserep-21-e920487]--[@b31-amjcaserep-21-e920487]\] could indicate either diagnosis, whereas the lack of D2-40 or CK5/6 and the presence of ER are counter to the usual immunohistochemistry of both WDPM and RMH.

Because the positive staining for EMA \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487],[@b7-amjcaserep-21-e920487],[@b9-amjcaserep-21-e920487],[@b18-amjcaserep-21-e920487],[@b19-amjcaserep-21-e920487],[@b27-amjcaserep-21-e920487]\], vimentin \[[@b13-amjcaserep-21-e920487],[@b19-amjcaserep-21-e920487],[@b28-amjcaserep-21-e920487]\], and BAP-1 \[[@b10-amjcaserep-21-e920487],[@b24-amjcaserep-21-e920487],[@b29-amjcaserep-21-e920487],[@b30-amjcaserep-21-e920487],[@b32-amjcaserep-21-e920487]\] observed in our case is indicative of both WDPM and serous papillary carcinoma ([Table 2](#t2-amjcaserep-21-e920487){ref-type="table"}), it did not assist our differential diagnosis. PAX8 has also been shown to be less useful in differentiating WDPM from serous papillary carcinoma due to crossover of the immunophenotypic patterns of PAX8 \[[@b5-amjcaserep-21-e920487]\]. However, the presence of calretinin, as in our case, is much more likely in WDPM \[[@b4-amjcaserep-21-e920487]--[@b16-amjcaserep-21-e920487],[@b18-amjcaserep-21-e920487]\] and occurs in a smaller percentage of cases of serous papillary carcinoma \[[@b5-amjcaserep-21-e920487],[@b23-amjcaserep-21-e920487]\] ([Table 2](#t2-amjcaserep-21-e920487){ref-type="table"}). Interestingly, the calcification in our case was positive for ER, which occurs commonly in serous papillary carcinoma but generally not in WDPM \[[@b23-amjcaserep-21-e920487],[@b33-amjcaserep-21-e920487]\]. In addition, the lack of D2-40 or CK5/6 would indicate serous papillary carcinoma over WDPM \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487],[@b34-amjcaserep-21-e920487],[@b35-amjcaserep-21-e920487],[@b37-amjcaserep-21-e920487]\]. The minimal positivity for CD56 in our case also points towards PSC \[[@b37-amjcaserep-21-e920487]\] versus WDPM or RMH \[[@b36-amjcaserep-21-e920487]\] ([Table 2](#t2-amjcaserep-21-e920487){ref-type="table"}). This case highlights the importance of the described stain selections. If a more limited diagnostic immunostain panel had been chosen in the current case, especially considering the patient's clinical course, the ER, PAX-8, and BAP1 positivity in particular may have led an investigator toward a diagnosis of a PSC, potentially significantly affecting clinical care.

A combination of baseline cytomorphologic, immunohistochemical and other special stains, along with a genetic analysis are generally required to sort through this differential, often requiring the services of an expert who sees a significant number of these cases in their primary or expert consultancy practices. Even then, the morphologic and immunohistochemical appearance may not allow for such distinctions. Ongoing observation of the patient, combined with a radiographic survey for potential primary tumors, may be required, while noting, as above, that malignant neoplasms of these types may arise primarily in the peritoneal lining.

In the present patient's case, positive staining for PAX8, EMA, and vimentin showed characteristics of carcinomas of mesenchymal origin from thyroid, urinary, reproductive, or kidney organ systems. However, the immunohistochemistry ([Table 2](#t2-amjcaserep-21-e920487){ref-type="table"}) and characteristics of the calcifications did not rule out the potential for other diagnoses. To reliably determine the possibility of a malignant lesion, it was necessary to examine the tissue for tumor cell invasion. When this was not observed during the examination, it supported the benign diagnosis. While performing this examination, it was imperative to note any rare occurrences of invasive-appearing benign tumors, particularly after surgery or following any other interventional procedures \[[@b23-amjcaserep-21-e920487],[@b47-amjcaserep-21-e920487]\].

Conclusions
===========

A large fatty and calcified mass was located and excised from the abdominal cavity of a post-menopausal woman with a family history of nondescript thyroid disease, multiple abdominal surgeries, and a personal 10-year history of chronic omental calcification. The mass was removed only after she developed symptoms of recurrent diffuse abdominal pain. The large size of the mass, along with the symptoms of abdominal discomfort, raised the concern that the lesion was a new malignancy rather than one associated with benign calcification. Although immunostaining of the calcified adipose tissue revealed an expression pattern akin to papillary carcinoma, it did not rule out the possibility of other diagnoses. We suggest that these calcifications are a benign, reactive phenomenon and that the abundance of psammoma bodies may be related to ongoing crops of papillary mesothelial hyperplasia and/or benign well-differentiated papillary mesothelioma.
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RMH

:   reactive mesothelial hyperplasia;

WDPM

:   well-differentiated papillary mesothelioma;

CK903

:   high-molecular-weight keratin;

EMA

:   epithelial membrane antigen;

PAX8

:   paired box immunostain 8;

CT

:   computed tomography;

EMM

:   epithelioid malignant mesothelioma;

PSC

:   papillary serous carcinoma,

PMM

:   peritoneal malignant mesothelioma.

![H&E photomicrographs: (**A**) 20×, (**B**) 100×, (**C**) 200×, and (**D**) 400× magnification. The lower powers highlight the dispersed nature of the papillary aggregates and the higher powers show their architectural detail.](amjcaserep-21-e920487-g001){#f1-amjcaserep-21-e920487}

![H&E with immunohistochemical stains, all 200× magnification. Central H&E image (**E**) was originally 100×, digitally expanded to 1550×. This particular proliferation has a propensity for lineage ambiguity, being positive for some stains expected in mesothelial proliferations, such as calretinin (**F**) and CK8 (**G**), and negative for D2-40 (**B**), CK5/6 (**D**), and negative (as expected) for CD56 (**I**). It was also positive for ER (**C**) and PAX-8 (**A**), which are commonly expressed in gynecologic papillary serous carcinoma, and positive for BAP1 (**H**), which is more commonly expressed in papillary serous carcinomas rather than mesothelial proliferations.](amjcaserep-21-e920487-g002){#f2-amjcaserep-21-e920487}

###### 

Well-differentiated papillary mesothelioma literature search.

  **First author**                                      **Date**   **Median age**   **M/F**   **No. patients**   **Tumor site**
  ----------------------------------------------------- ---------- ---------------- --------- ------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Our case                                              2019       68               0/1       1                  Omentum
  Kim \[[@b4-amjcaserep-21-e920487]\]                   2019       64               5/7       12                 Peritoneum, omentum, pelvic
  Sun \[[@b5-amjcaserep-21-e920487]\]                   2018       42               58/17     75                 Peritoneum, omentum, mesentery, Douglas pouch, ligament of the uterus, serosal surfaces of the ovary, fallopian tube, uterus, stomach, intestines, pleura, testicular tunica vaginalis, and inguinal hernia sac
  Bazine \[[@b6-amjcaserep-21-e920487]\]                2017       36               1/0       1                  Peritoneum
  Nasit \[[@b7-amjcaserep-21-e920487]\]                 2014       28               0/1       1                  Peritoneum, omentum, urinary bladder
  Irwin \[[@b8-amjcaserep-21-e920487]\]                 2014       68               0/1       1                  Peritoneum, omentum
  Washimi \[[@b9-amjcaserep-21-e920487]\]               2013       58               0/1       1                  Peritoneum
  Ribeiro \[[@b10-amjcaserep-21-e920487]\]              2013       50               0/2       2                  Peritoneum, pleura
  Malpica \[[@b11-amjcaserep-21-e920487]\]              2012       47               0/26      26                 Peritoneum, omentum, pelvis, fallopian tube, mesentery, cul-de-sac, colon, ovary, uterine serosa
  Nemoto \[[@b12-amjcaserep-21-e920487]\]               2012       73               0/1       1                  Peritoneum, omentum, stomach, colon
  Hatano \[[@b13-amjcaserep-21-e920487]\]               2012       45               1/0       1                  Peritoneum, omentum, stomach, colon
  Ikeda \[[@b14-amjcaserep-21-e920487]\]                2010       73               0/1       1                  Peritoneum, omentum
  Martinez-Consuegra \[[@b15-amjcaserep-21-e920487]\]   2008       46               0/1       1                  Peritoneum
  Hoekstra \[[@b16-amjcaserep-21-e920487]\]             2005       74               0/1       1                  Peritoneum
  Haba \[[@b17-amjcaserep-21-e920487]\]                 2003       44               0/1       1                  Peritoneum
  Diaz \[[@b18-amjcaserep-21-e920487]\]                 2002       41               0/1       1                  Peritoneum, pelvis
  Hoekman \[[@b19-amjcaserep-21-e920487]\]              1996       36               0/3       3                  Peritoneum
  Daya \[[@b20-amjcaserep-21-e920487]\]                 1990       41               4/18      22                 Omentum, pelvis
  Lovell \[[@b21-amjcaserep-21-e920487]\]               1990       11               0/1       1                  Peritoneum

  **First Author**                                      **Other Conditions**                                                                                                                                                                                                                                                                                                                                                                                       **Tumor size**                              **Immunostains**                                                 **Calcification**   **Psammomatous Masses**
  ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------------- ------------------- -------------------------
  Our Case                                              Past history includes benign breast mass, hysterectomy due to leiomyoma, appendectomy                                                                                                                                                                                                                                                                                                                      8.5×6.5×1.8 cm                              +Calretinin, +PAX8, +EMA, +vimentin, −CK903                      Yes                 Yes
  Kim \[[@b4-amjcaserep-21-e920487]\]                   Cecal carcinoma, uterine leiomyoma, hepatocellular carcinoma, gastric GIST, uterine cervical carcinoma, duct carcinoma, gastric carcinoma, colorectal carcinoma                                                                                                                                                                                                                                            0.1--3 cm                                   100% +calretinin, 28.6% +PAX8, 100% focally +EMA, 91.7% +CK5/6   NO                  NO
  Sun \[[@b5-amjcaserep-21-e920487]\]                   52% of WDPM lesions found during surgery for uterine leiomyoma, ovarian cysts endometriosis of ovary, caesarean delivery, uterine cervix carcinoma, endometrial carcinoma, endometrioid adenocarcinoma, pelvic endometriosis, ovarian teratoma, granulosa cell tumor of ovary. 47% found during surgery for lesions such as gastrointestinal stromal tumor, inguinal hernia, scrotal nodule, lung cancer   0.2--6 cm, \<2 cm in 80% of the pure WDPM   100% +calretinin, 94% +PAX8, 35% +EMA                            NR                  NR
  Bazine \[[@b6-amjcaserep-21-e920487]\]                NR                                                                                                                                                                                                                                                                                                                                                                                                         5 mm                                        +Calretinin                                                      NR                  NR
  Nasit \[[@b7-amjcaserep-21-e920487]\]                 NR                                                                                                                                                                                                                                                                                                                                                                                                         0.8--7.8cm                                  +Calretinin                                                      NO                  NO
  Irwin \[[@b8-amjcaserep-21-e920487]\]                 Gastric cancer                                                                                                                                                                                                                                                                                                                                                                                             NR                                          +calretinin                                                      NR                  Occasional
  Washimi \[[@b9-amjcaserep-21-e920487]\]               Rectal carcinoid                                                                                                                                                                                                                                                                                                                                                                                           5 mm (2004), 2cm in 2011                    +Calretinin, +EMA                                                NR                  NR
  Ribeiro \[[@b10-amjcaserep-21-e920487]\]              Pleural diabetes, corneal ulcers                                                                                                                                                                                                                                                                                                                                                                           NR                                          +Calretinin (in one case), +BAP-1                                NR                  NR
  Malpica \[[@b11-amjcaserep-21-e920487]\]              Pancreatic carcinoma, gallbladder carcinoma, urachal carcinoma, inguinal hernia, paraovarian cyst, ovarian serous cystadenofibroma, ovarian Mullerian tumor, colonic carcinoma, leiomyoma                                                                                                                                                                                                                  0.1--2 cm                                   100% +calretinin, 3.8% of cases only 42% of cases had data                           3.8%
  Nemoto \[[@b12-amjcaserep-21-e920487]\]               NR                                                                                                                                                                                                                                                                                                                                                                                                         5 cm                                        +Calretinin                                                      NR                  NR
  Hatano \[[@b13-amjcaserep-21-e920487]\]               Adenomatoid tumor                                                                                                                                                                                                                                                                                                                                                                                          2.4 cm                                      +Vimentin, +calretinin, −EMA                                     NR                  NR
  Ikeda \[[@b14-amjcaserep-21-e920487]\]                NR                                                                                                                                                                                                                                                                                                                                                                                                         NR                                          +Calretinin                                                      NR                  NR
  Martinez-Consuegra \[[@b15-amjcaserep-21-e920487]\]   Cholecystitis                                                                                                                                                                                                                                                                                                                                                                                              5 mm to 1.0 cm                              +Calretinin                                                      NR                  Some
  Hoekstra \[[@b16-amjcaserep-21-e920487]\]             Ovarian serous cystadenoma, hepatic lesions                                                                                                                                                                                                                                                                                                                                                                \<1 cm peritoneum                           +Calretinin                                                      Yes                 NR, 22% in lit. search
  Haba \[[@b17-amjcaserep-21-e920487]\]                 Adenomyosis, hypermenorrhea                                                                                                                                                                                                                                                                                                                                                                                0.5--2.0 cm                                 NR                                                               NR                  NR
  Diaz \[[@b18-amjcaserep-21-e920487]\]                 Ovarian cyst                                                                                                                                                                                                                                                                                                                                                                                               5.0 cm                                      +Calretinin                                                      NR                  NR
  Hoekman \[[@b19-amjcaserep-21-e920487]\]              Appendicitis, hepatic lesion                                                                                                                                                                                                                                                                                                                                                                               NR                                          100% +Keratin, 100% +vimentin, 33%+ EMA, 66% −EMA                NR                  NR
  Daya \[[@b20-amjcaserep-21-e920487]\]                 Small tumor foci on the ovarian surfaces, in addition to other tumor nodules in abdomen, ovarian masses, ovarian endometrioid carcinoma, benign cystic teratoma                                                                                                                                                                                                                                            0.5--2.0 cm                                 NR                                                               4.5% of cases       22% of cases
  Lovell \[[@b21-amjcaserep-21-e920487]\]               NR                                                                                                                                                                                                                                                                                                                                                                                                         NR                                          NR                                                               Yes                 Yes

NR -- not reported; NO -- not observed

###### 

Immunohistochemical comparison for this case versus WDPM, RMH, and PSC.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Antibody**   **Our case**                       **WDPM**                                                                                                                                                                                                                                                                                                                    **RMH**                                                                                                                     **PSC**
  -------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Calretinin     Positive                           100% positive \[[@b4-amjcaserep-21-e920487]--[@b16-amjcaserep-21-e920487],[@b18-amjcaserep-21-e920487]\]                                                                                                                                                                                                                    96% positive \[[@b22-amjcaserep-21-e920487]\]                                                                               0--38% positive \[[@b23-amjcaserep-21-e920487]\], usually negative \[[@b5-amjcaserep-21-e920487]\]

  PAX8           Positive                           29 to 94% positive \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487]\]                                                                                                                                                                                                                                              55% positive \[[@b24-amjcaserep-21-e920487]\]                                                                               Mostly positive \[[@b23-amjcaserep-21-e920487]\]

  EMA            Positive (focally)                 35% positive \[[@b5-amjcaserep-21-e920487]\], positive \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487],[@b7-amjcaserep-21-e920487],[@b9-amjcaserep-21-e920487],[@b18-amjcaserep-21-e920487],[@b19-amjcaserep-21-e920487]\], negative \[[@b13-amjcaserep-21-e920487]\]                                             0% positive, \[[@b22-amjcaserep-21-e920487],[@b25-amjcaserep-21-e920487]\], 20% positive \[[@b26-amjcaserep-21-e920487]\]   Usually positive \[[@b27-amjcaserep-21-e920487]\]

  Vimentin       Focally positive                   100% positive \[[@b13-amjcaserep-21-e920487],[@b19-amjcaserep-21-e920487]\]                                                                                                                                                                                                                                                 Positive \[[@b25-amjcaserep-21-e920487]\]                                                                                   Usually positive \[[@b28-amjcaserep-21-e920487]\]

  Cytokeratin    CK5/6: negative                    CK5/6: 92--93% positive \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487]\], positive \[[@b6-amjcaserep-21-e920487] [@b9-amjcaserep-21-e920487]--[@b11-amjcaserep-21-e920487],[@b15-amjcaserep-21-e920487],[@b18-amjcaserep-21-e920487]\], negative \[[@b7-amjcaserep-21-e920487], [@b16-amjcaserep-21-e920487]\]   CK5/6: positive \[[@b25-amjcaserep-21-e920487]\]                                                                            CK5/6: 22--35% positive \[[@b23-amjcaserep-21-e920487]\]

  BAP1           Variable but moderately positive   100% positive \[[@b29-amjcaserep-21-e920487]\]\                                                                                                                                                                                                                                                                             86% positive \[[@b31-amjcaserep-21-e920487]\]                                                                               100% positive \[[@b24-amjcaserep-21-e920487]\], 99.7% positive \[[@b32-amjcaserep-21-e920487]\]
                                                    100% positive[^\*^](#tfn3-amjcaserep-21-e920487){ref-type="table-fn"} \[[@b30-amjcaserep-21-e920487]\], positive \[[@b10-amjcaserep-21-e920487]\]                                                                                                                                                                                                                                                                                                       

  ER             Focally positive                   Usually negative \[[@b33-amjcaserep-21-e920487]\], negative \[[@b7-amjcaserep-21-e920487], [@b8-amjcaserep-21-e920487]\]                                                                                                                                                                                                    NA                                                                                                                          60--93% positive \[[@b23-amjcaserep-21-e920487]\]

  D2-40          Negative                           Positive \[[@b4-amjcaserep-21-e920487],[@b5-amjcaserep-21-e920487],[@b9-amjcaserep-21-e920487],[@b13-amjcaserep-21-e920487],[@b14-amjcaserep-21-e920487]\]                                                                                                                                                                  Positive \[[@b25-amjcaserep-21-e920487]\]                                                                                   Negative \[[@b34-amjcaserep-21-e920487]\], 23.2% positive \[[@b35-amjcaserep-21-e920487]\]

  CD56           Minimal positivity                 NA                                                                                                                                                                                                                                                                                                                          Negative \[[@b25-amjcaserep-21-e920487]\], 100% negative \[[@b36-amjcaserep-21-e920487]\]                                   33% positive[^\*\*^](#tfn4-amjcaserep-21-e920487){ref-type="table-fn"} \[[@b37-amjcaserep-21-e920487]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

WDPM -- well-differentiated papillary mesothelioma; RMH -- reactive mesothelial hyperplasia; PSC -- papillary serous carcinoma.

Pure WDPM;

serous borderline tumors.
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